A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

BACKGROUND: The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. Treatment with angiotensin receptor blockers (ARBs), such as losartan, may mitigate these effects, though induction of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :EClinicalMedicine
Главные авторы: Puskarich, Michael A., Cummins, Nathan W., Ingraham, Nicholas E., Wacker, David A., Reilkoff, Ronald A., Driver, Brian E, Biros, Michelle H., Bellolio, Fernanda, Chipman, Jeffrey G., Nelson, Andrew C., Beckman, Kenneth, Langlois, Ryan, Bold, Tyler, Aliota, Matthew T., Schacker, Timothy W., Voelker, Helen T., Murray, Thomas A, Koopmeiners, Joseph S., Tignanelli, Christopher J.
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2021
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225661/
https://ncbi.nlm.nih.gov/pubmed/34195577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100957
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы